Swiss pharmaceutical company Curatis Holding AG (SIX:CURN) announced on Friday that it has signed a distribution agreement with healthcare company Phoenix Labs (Ireland) covering four products in Switzerland.
The portfolio includes treatments in pain management and urology and will be available from October 2025.
The products generated around CHF5m in Swiss revenues in 2024.
Under the agreement, Curatis will act as marketing authorisation holder and assume responsibility for regulatory, quality and pharmacovigilance services on behalf of Phoenix Labs in Switzerland.
(EUR1=CHF0.94)
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli